The author has completed the ICMJE form and declares the following conflicts of interest: She is a research assistant and principal investigator at a fetal medicine centre involved in the nipocalimab ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

Another promising development is nipocalimab, which has been identified as a product with over $5 billion peak sales potential. Nipocalimab has shown clinical effect in four autoantibody-driven ...

Another promising development is nipocalimab, which has been identified as a product with over $5 billion peak sales potential. Nipocalimab has shown clinical effect in four autoantibody-driven ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology. J&J is testing the investigational FcRn blocker in a broad ...

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational ...

Efgartigimod shows success in myositis trials after prior approvals in gMG/CIDP. Both IV and subcutaneous forms are approved, with Phase 3 myositis trials starting. Q4 2024 revenue beats estimates ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.